BioXcel Therapeutics

$45.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.27 (+0.59%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell BTAI and other stocks, options, and ETFs commission-free!

About BTAI

BioXcel Therapeutics, Inc. Common Stock, also called BioXcel Therapeutics, is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. The listed name for BTAI is BioXcel Therapeutics, Inc. Common Stock.

CEO
Vimal D. Mehta
Employees
24
Headquarters
New Haven, Connecticut
Founded
2017
Market Cap
1.11B
Price-Earnings Ratio
Dividend Yield
Average Volume
387.07K
High Today
$46.03
Low Today
$44.50
Open Price
$45.45
Volume
207.67K
52 Week High
$71.50
52 Week Low
$5.58

Collections

BTAI Earnings

-$1.07
-$0.71
-$0.36
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 9, Pre-Market

You May Also Like